Search results for "bowel"

showing 10 items of 637 documents

Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel…

2015

Earlier studies showed that the compatible solute ectoine (1) given prophylactically before induction of colitis by 2,4,6-trinitrobenzenesulfonic acid (TNBS) in rats prevented histological changes induced in the colon and the associated rise in inflammatory mediators. This study was therefore conducted to investigate whether ectoine (1) and its 5α-hydroxy derivative (2) would also be effective in treating an already established condition. Two days after inducing colitis in rats by instilling TNBS/alcohol in the colon, animals were treated orally once daily for 1 week with either 1 or 2 (50, 100, 300 mg/kg). Twenty-four hours after the last drug administration rats were sacrificed. Ulcerativ…

MaleColonInterleukin-1betaPharmaceutical SciencePharmacologyEctoineInflammatory bowel diseaseAnalytical Chemistrychemistry.chemical_compoundDrug DiscoverymedicineAnimalsHumansRats WistarColitisPeroxidasePharmacologyBacteriaMolecular StructurebiologyTumor Necrosis Factor-alphaChemistryOrganic ChemistryAmino Acids DiaminoGlutathioneColitisInflammatory Bowel DiseasesIntercellular Adhesion Molecule-1medicine.diseasebiology.organism_classificationGlutathioneRatsIntestinesSolutionsTrinitrobenzenesulfonic AcidComplementary and alternative medicineBiochemistryMyeloperoxidasebiology.proteinMolecular MedicineEgyptOsmoprotectantTumor necrosis factor alphaBacteriaJournal of Natural Products
researchProduct

Probiotic mixture supplementation in the preventive management of trinitrobenzenesulfonic acid-induced inflammation in a murine model

2016

Inflammatory bowel diseases (IBD) are characterized by inflammatory conditions of the intestine. Probiotic bacteria (PB) can have beneficial effects in several gastrointestinal disorders. The objectives of this study were: (i) to provide an acute experimental IBD model induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS) in CD-1 mice, and (ii) to assess the preventive effects of Citogenex (Lactobacillus casei and Bifidobacterum lactis) supplementation on intestinal tissues and microbiota. Mice were inoculated intrarectally with saline, ethanol or different TNBS solutions. 1%TNBS induced clinical signs of colitis (P less than 0.01) and histological damage (P less than 0.01). Based on these r…

MaleColonProbioticsColitisInflammatory Bowel Diseasesdigestive systemdigestive system diseasesGastrointestinal MicrobiomeIBD ProbioticsDisease Models AnimalLacticaseibacillus caseiMiceBifidobacterium animalisTrinitrobenzenesulfonic AcidAnimals Outbred StrainsAnimalsIBD probioticinduced-colitis model disease activity index microbiota
researchProduct

Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study

2019

Abstract Background Few data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis. Aims to describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription. Methods This multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD. Results Seventy patients (64 Crohn’s disease…

MaleCrohn’s diseaseSettore MED/16 - REUMATOLOGIAPsoriaticCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Hepatology; GastroenterologyInflammatory bowel disease0302 clinical medicineClinical endpointCrohn's disease Psoriasis Psoriatic arthritis Ulcerative colitis UstekinumabCrohn's diseaseSettore MED/12 - GastroenterologiaGastroenterologyMiddle AgedUlcerative colitisCrohn's diseaseTreatment OutcomeItaly030220 oncology & carcinogenesisPsoriatic arthritis030211 gastroenterology & hepatologyFemaleUstekinumabmedicine.drugAdultmedicine.medical_specialty03 medical and health sciencesPsoriatic arthritisCrohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; Ustekinumab; Adult; Aged; Arthritis Psoriatic; Dermatologic Agents; Female; Humans; Inflammatory Bowel Diseases; Italy; Logistic Models; Male; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome; Ustekinumab; Young AdultYoung AdultInternal medicinePsoriasisUstekinumabmedicineHumansPsoriasisAgedRetrospective StudiesHepatologybusiness.industryArthritisArthritis Psoriaticmedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesCrohn’s disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis; UstekinumabLogistic ModelsUlcerative colitisConcomitantDermatologic Agentsbusiness
researchProduct

Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammator…

2019

BACKGROUND Disease phenotype and outcome of late-onset Crohn's disease are still poorly defined. METHODS In this Italian nationwide multicentre retrospective study, patients diagnosed ≥65 years (late-onset) were compared with young adult-onset with 16-39 years and adult-onset Crohn's disease 40-64 years. Data were collected for 3 years following diagnosis. RESULTS A total of 631 patients (late-onset 153, adult-onset 161, young adult-onset 317) were included. Colonic disease was more frequent in late-onset (P < 0005), stenosing behaviour was more frequent than in adult-onset (P < 0003), but fistulising disease was uncommon. Surgery rates were not different between the three age groups. Syste…

MaleDiseaseConstriction PathologictumoursInflammatory bowel diseaseLate Onset DisordersCohort Studiessurgery0302 clinical medicineCrohn DiseaseLate Onset DisordersMedicineYoung adultDigestive System Surgical ProceduresCrohn's diseaseGastroenterologyIleitisMiddle AgedColitisItaly030220 oncology & carcinogenesisoutcome030211 gastroenterology & hepatologyFemaleColorectal NeoplasmsCohort studysteroidsAdultmedicine.medical_specialtyAdolescentcomorbiditieselderly03 medical and health sciencesYoung AdultInternal medicineIntestinal FistulaHumansImmunologic FactorsGlucocorticoidsAgedRetrospective StudiesPolypharmacyHepatologybusiness.industrythiopurinesRetrospective cohort studymedicine.diseasecomorbidities; elderly; outcome; steroids; surgery; thiopurines; tumoursPolypharmacyTumor Necrosis Factor Inhibitorsbusiness
researchProduct

Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease

2019

[EN] Silica mesoporous microparticles loaded with both rhodamine B fluorophore (S1) or hydrocortisone (S2), and capped with an olsalazine derivative, are prepared and fully characterized. Suspensions of Si and S2 in water at an acidic and a neutral pH show negligible dye/drug release, yet a notable delivery took place when the reducing agent sodium dithionite is added because of hydrolysis of an azo bond in the capping ensemble. Additionally, olsalazine fragmentation induced 5-aminosalicylic acid (5-ASA) release. In vitro digestion models show that S1 and S2 solids are suitable systems to specifically release a pharmaceutical agent in the colon. In vivo pharmacokinetic studies in rats show …

MaleHydrocortisoneTECNOLOGIA DE ALIMENTOSReducing agentPharmaceutical Science02 engineering and technologyMesoporous silica microparticles030226 pharmacology & pharmacyInflammatory bowel diseaseSodium dithionite03 medical and health scienceschemistry.chemical_compoundHydrolysisDrug Delivery Systems0302 clinical medicineQUIMICA ORGANICAIn vivoDrug DiscoveryQUIMICA ANALITICAmedicineRhodamine BAnimalsGated materialsRats WistarMesalamineOlsalazineRhodaminesColon targeted releaseQUIMICA INORGANICAMesoporous silicaColitisInflammatory Bowel DiseasesSilicon Dioxide021001 nanoscience & nanotechnologySmart drug delivery materialsRatschemistryDrug deliveryMolecular Medicine0210 nano-technologymedicine.drugNuclear chemistry
researchProduct

Lactobacillus casei and Bifidobacterium lactis supplementation reduces tissue damage of intestinal mucosa and liver after 2,4,6-trinitrobenzenesulfon…

2014

Probiotics (PB) are living microorganisms that act as a commensal population in normal intestines and confer numerous beneficial effects on the host. The introduction of probiotics in the treatment of inflammatory bowel disease (IBD) prolongs remission. The aim of this study was to investigate the intestinal and hepatic effects of PB supplementation in an experimental IBD model in mice induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS). In the first step of the experimental procedure, CD-1 male mice, 5 to 6 weeks old, were randomly divided into 3 groups and inoculated intrarectally with, respectively, saline, alcohol, or TNBS to assess the experimental IBD model. In the second step, mice…

MaleLacticaseibacillus caseiMiceLiverTrinitrobenzenesulfonic AcidProbioticsDietary SupplementsAnimalsHumansBifidobacteriumIntestinal MucosaInflammatory Bowel DiseasesIntestinal Inflammation intestinal cancer microbiotaprobiotic supplementation large bowel liver apoptosis
researchProduct

Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel prepa…

2019

Bowel preparation (BP) for colonoscopy induces significantly changes in gut microbiota and elicit intestinal symptoms. Impaired microbiota causes an intestinal dysbiosis. Consequently, probiotics may counterbalance the disturbed microbiota after BP. The current survey evaluated the efficacy and safety of Abincol®,an oral nutraceuticalcontaining a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 2,979 outpatients (1,579 males and 1,400 females, mean age 56 years) undergoing BP. Patients took 1 stick/daily for 4 w…

MaleLactobacillus delbrueckiigut microbiotaProbioticsColonoscopyMiddle AgedLactobacillusPreoperative Carebowel preparationDysbiosisHumansFemaleOriginal Articlesurveybowel preparation gut microbiota colonoscopy probiotics surveyLactobacillus plantarumActa bio-medica : Atenei Parmensis
researchProduct

Nutritional Status and Selected Adipokines in Children with Irritable Bowel Syndrome

2022

Background: The aim of this study was to assess the nutritional status and serum concentrations of adipokines in children with irritable bowel syndrome (IBS) and healthy controls. We also sought to evaluate their relation to metabolic parameters. Methods: We studied 33 IBS patients (11 girls, 22 boys) aged 5–17 years and 30 healthy age-matched controls (11 girls, 19 boys). The analysis included anthropometric measurements, body composition parameter measurements using bioimpedance, and biochemical tests and measurements of serum concentrations of leptin, adiponectin, chemerin, and omentin-1. Results: The results of the anthropometric measurements were comparable between the patients and the…

MaleLeptinNutrition and DieteticsAdolescentNutritional StatusIrritable Bowel SyndromeAdipokinesChild Preschoolirritable bowel syndrome; leptin; adiponectin; chemerin; omentin-1; childrenHumansCytokinesIntercellular Signaling Peptides and ProteinsFemaleAdiponectinChemokinesInsulin ResistanceChildFood ScienceNutrients
researchProduct

Inflammation and Aortic Pulse Wave Velocity: A Multicenter Longitudinal Study in Patients With Inflammatory Bowel Disease

2019

Background Inflammatory bowel disease ( IBD ) is characterized by a low prevalence of traditional risk factors, an increased aortic pulse‐wave velocity ( aPWV ), and an excess of cardiovascular events. We have previously hypothesized that the cardiovascular risk excess reported in these patients could be explained by chronic inflammation. Here, we tested the hypothesis that chronic inflammation is responsible for the increased aPWV previously reported in IBD patients and that anti‐TNFa (anti‐tumor necrosis factor‐alpha) therapy reduce aPWV in these patients. Methods and Results This was a multicenter longitudinal study. We enrolled 334 patients: 82 patients with ulcerative colitis, 85 pati…

MaleLongitudinal studyTime FactorsSettore MED/09 - Medicina InternaAorta ThoracicBlood Pressure030204 cardiovascular system & hematologyGastroenterologyInflammatory bowel diseaseulcerative coliti0302 clinical medicineRisk Factorsarterial stiffneVascular DiseaseTumor necrosis factor-alphaEndoscopy Digestive SystemProspective Studies030212 general & internal medicinePulse wave velocityOriginal ResearchCrohn diseasetumor necrosis factor‐alphaUlcerative colitisC-Reactive Proteinarterial stiffnessCardiovascular DiseasesHypertensionFemaleTumor necrosis factor alphamedicine.symptomCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtypulse wave velocityInflammationPulse Wave Analysis03 medical and health sciencesVascular StiffnessInternal medicinemedicineHumansIn patientulcerative colitisbusiness.industryInflammatory Bowel Diseasesmedicine.diseasearterial stiffness; Crohn disease; inflammation; pulse wave velocity; tumor necrosis factor‐alpha; ulcerative colitis; Cardiology and Cardiovascular MedicineinflammationArterial stiffnessbusinessBiomarkersFollow-Up Studies
researchProduct

Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas

2020

Abstract Background Small bowel adenocarcinoma is a relatively rare cancer, often diagnosed in an advanced stage. In localized and resectable disease, surgery alone or in combination with adjuvant chemotherapy is the mainstay of treatment. In the recently published National Comprehensive Cancer Network Clinical Practice guidelines, criteria for selecting patients with stage II small bowel adenocarcinoma to receive adjuvant chemotherapy are provided, and they are mainly extrapolated from studies on colorectal cancer. Patients and Methods In the present study, we aimed to verify whether mismatch repair deficiency phenotype, high-risk pathologic features (including T4, positive resection margi…

MaleOncologyColorectal cancerDNA Mismatch RepairCOLORECTAL-CANCERSettore MED/120302 clinical medicinePMS2small bowel adenocarcinomaMismatch Repair Endonuclease PMS20303 health sciencesPrognosisMMRMutS Homolog 2 ProteinOncologyCARCINOMAS030220 oncology & carcinogenesisimmunohistochemistryMismatch Repair Status small bowel adenocarcinomaFemaleMicrosatellite InstabilityDNA mismatch repairMutL Protein Homolog 1Colorectal Neoplasmsstage IImedicine.medical_specialtyhigh-risk pathologic featuresDNA Mismatch Repair; Female; Humans; Male; Microsatellite Instability; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; MutS Homolog 2 Protein; Prognosis; Adenocarcinoma; Colorectal Neoplasmssmall bowel adenocarcinoma; mismatch repair statusAdenocarcinomaNO03 medical and health sciencessmall bowel carcinomahistotypeInternal medicineTranslational ResearchmedicineHumansmismatch repair status030304 developmental biologysmall bowel adenocarcinomasbusiness.industryCancerMicrosatellite instabilityMismatch Repair ProteinAdenocarcinoma IBD Cancermedicine.diseasedigestive system diseasesMSH6COLORECTAL-CANCER; CARCINOMAS; CONSENSUSsmall bowel carcinoma MMR immunohistochemistryMismatch repair Small bowel AdenocarcinomaMSH2Mismatch repair status; stage II; small bowel adenocarcinomas; histotype; high-risk pathologic featuresSurgeryCONSENSUSbusiness
researchProduct